Long-acting risperidone improves negative symptoms in stable psychotic patients

Journal of Psychopharmacology

Volumn 22, Issue 3, 2008, Pages 254-261

  Curtis, V A ^a   Katsafouros, K ^b   Moller H J ^c   Medori, R ^d   Sacchetti, E ^e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Dromokaition State Hospital   (Greece)

^c UNIVERSITY OF MUNICH   (Germany)

^d Janssen Cilag EMEA Belgium   (Belgium)

^e UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Atypical antipsychotic; Long acting; Negative symptoms; Risperidone; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; LONG ACTING DRUG; RISPERIDONE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DATA INTERPRETATION, STATISTICAL; DELAYED-ACTION PREPARATIONS; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 45349109309     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107082119     Document Type: Article

References (30)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4 th edn. American Psychiatric Association, Washington, DC
2. Chouinard G., Margolese H.C. (2005) Manual for the extrapyramidal symptom rating scale. Schizophr Res 76: 247-265
3. Davis J.M., Chen N. (2002) Clinical profile of an atypical antipsychotic: Risperidone. Schizophr Bull 28: 43-61
4. Eaton W.W., Thara R., Federman B., Melton B., Liang K. (1995) Structure and course of positive and negative symptoms in schizophrenia. Arch Gen Psychiatry 52: 127-134
5. Erhart S M., Marder S R., Carpenter W.T. (2006) Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 32: 234-237
6. Ertuǧrul A., Uluǧ B. (2002) The influence of neurocognitive deficits and symptoms on disability in schizophrenia. Acta Psychiatr Scand 105: 196-201
7. Fleischhacker W W., Eerdekens M., Karcher K., Remington G., Llorca P M., Chrzanowski W., Martin S., Gefvert O. (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J Clin Psychiatry 64: 1250-1257
8. Guy W. (1976) Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology, Vol. 7 6. US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Rockville, MD
9. Han C., LeeB.H., Kim Y.K., Lee H.J., Kim H., Kim S.L., Lee M.S., Joe S.H., Ham B.J., Jung I.K. (2005) Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics. Prim Care Comm Psychiatr 10: 119-124
10. Janssen B., Gaebel W., Haerter M., Komaharadi F., Lindel B., Weinmann S. (2006) Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology 187: 229-236
11. Kay S.R., Fiszbein A., Opler L.A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276
12. King D.J. (1998) Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 8: 33-42
13. Kirkpatrick B., Fenton W S., Carpenter W.T., Marder S R. (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32: 214-219
14. Lasser R A., Bossie C A., Gharabawi G.M., Baldessarini R.J. (2005) Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 8: 427-438
15. Leucht S., Heres S. (2006) Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67: 3-8
16. Mann K., Rossbach W., Müller M.J., Müller-Siechender F., Pott T., Linde I., Dittmann R.W., Hiemke C. (2006) Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31: 256-264
17. Marder SR, Davis JM, Chouinard G. (1997) The effect of risperidone on the five dimensions of schizophrenia derived by factor analysis: a combined results of the North American trials. J Clin Psychiatry 58: 538-546
18. Martin J.L.R., Pérez V., Sacristán M., Rodríguez- Artalejo F., Martínez C., Álvarez E. (2006) Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry 21: 11-20
19. Medori R., Mannaert E., Gruender G. (2006) Plasma antipsychotic concentrations and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 16: 233-240
20. Möller H.J. (2005 a) Risperidone: a review. Expert Opin Pharmacother 6: 803-818
21. Möller H.J. (2005 b). Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur Psychiatry 20: 379-385
22. Möller H J, Llorca P M, Sacchetti E, Martin S D, Medori R, Parellada E, StoRMi Study Group (2005). Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20: 121-130
23. Perkins D.O. (2002) Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63: 1121-1128
24. Potkin S G., Alva G., Fleming K., Anand R., Keator D., Carreon D., Doo M., Jin Y., Wu J.C., Fallon JH (2002) A PET study of the pathophysiology of negative symptoms in schizophrenia. Am J Psychiatry 159: 227-237
25. Riedel M., Müller N., Strassnig M., Spellmann I., Engel R.R., Musil R., Dehning S., Douhet A., Schwarz M.J., Möller H.J. (2005) Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Clin Neurosci 255: 432-437
26. Storosum J G., Elferink J., van Zwieten B J., van Strik R., Hoogendijk W J., Broekmans A W. (2002) Amisulpride: is there a treatment for negative symptoms in schizophrenia patients ? Schizophr Bull 28: 193-201
27. Strous R D., Kupchik M., Roitman S., Schwartz S., Gonen N., Mester R., Weizman A., Spivak B. (2006) Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Hum Psychopharmacol 21: 235-243
28. Tandon R. (2004) Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum Psychopharmacol 19: 559-563
29. Ware J.E., Sherbourne C.D. (1992) The MOS 36-Item Short-Form Health Survey (SF-36®). I. Conceptual framework and item selection. Med Care 30: 473-483
30. Wiersma D., Nienhuis F.J., Sloof C.J., Giel R. (1998) Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizo Bull 24: 75-85